ICCM - IceCure Medical Ltd Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

ICCM

ICECURE MEDICAL LTD

NASDAQ

$1.13

▼ DOWN 1.74% (-0.02)

KEY STATISTICS

Market Cap$2.54 M

52w High$30.30

52w Low$1.05

Dividend Yield—

Frequency—

P/E-0.17

Volume311.48K

Shares Out.2.25M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Eyal Shamir

ABOUT

SECTOR

Healthcare

WENT PUBLIC

August 26, 2021

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

PRICE TARGET

Target High$1.00

Target Low$1.00

Target Median$1.00

Target Consensus$1.00

UPCOMING EARNINGS

DateNov 18, 2026

DayWednesday

Rev. Est.$876.50K

NOV

WED

SPLIT RECORD

DATE	TYPE	RATIO
2026-06-04	Reverse	1:30
2021-08-09	Reverse	1:8

INSTITUTIONAL OWNERSHIP

SHARES OWNED

100.00%

HOLDERS

TOP 8 OF 28 · RANKED BY POSITION SIZE

Armistice Capital, LLC

Jane Street Group, LLC

109.6K sh

$66.89K

Concurrent Investment Advisors, LLC

78.3K sh

$47.76K

Warberg Asset Management LLC

Two Sigma Securities, LLC

PRICE

$1.13 ▼ DOWN 1.74% (−$0.02)

OVERLAYS

About IceCure Medical Ltd

https://www.icecure-medical.com ↗

IceCure Medical Ltd, founded in 2006 in Caesarea, Israel, develops and commercializes cryoablation devices like the ProSense system for tumor treatment, primarily focusing on freezing tumors such as breast cancer.

INDUSTRY

Medical - Devices

A PRODUCT ICECURE MEDICAL LTD IS KNOWN FOR

ProSense® Cryoablation System

IceCure's ProSense® Cryoablation System is a minimally invasive device using liquid nitrogen to freeze and destroy benign and cancerous tumors across multiple organs, offering an alternative to surgery.

COMPETITORS

COMPETITOR

IceCure Medical in 2025

SENTIMENT: + POSITIVE

REGULATORY · OCTOBER 2025

IceCure Medical's ProSense® Cryoablation System Granted FDA Marketing Authorization for Breast Cancer Treatment

In a landmark decision, the U.S. Food and Drug Administration (FDA) granted marketing authorization for IceCure's ProSense® system for the local treatment of low-risk, early-stage breast cancer in women aged 70 and older. This approval marked ProSense® as the first and only minimally invasive cryoablation device authorized for this indication in the U.S., opening up a significant market and offering a new treatment alternative to surgery for an estimated 200,000 patients annually.

MARKET EXPANSION · OCTOBER 2025 · IN PROGRESS

IceCure Medical Pivots to Aggressive U.S. Commercialization Following Landmark FDA Approval for Breast Cancer Treatment

Following the October 2025 FDA marketing authorization for its ProSense® cryoablation system, IceCure Medical made a pivotal strategic decision to focus on and scale its commercial operations in the U.S. This shift is aimed at establishing ProSense® as a new standard of care for low-risk breast cancer in eligible patients, representing the company's most significant move to penetrate a major new market.

Latest News

PRNEWSWIRE · OCT 6, 2026

IceCure Expands ProSense® ChoICE Study for Low-Risk Breast Cancer adding Legacy Health in Portland, OR as U.S. Clinical Site

CAESAREA, Israel, Oct. 6, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced the addition of Legacy Health in Portland, Oregon, with its Legacy Medical Group–Surgical Oncology at Good Samaritan Medical Center , as a new U.S. clinical site for its post-marketing study (the "ChoICE Study") evaluating the use of ProSense® cryoablation in the local treatment of low-risk breast cancer.

READ ARTICLE

EARLIER COVERAGE

DEFENSE WORLD · OCT 1, 2026

IceCure Medical Ltd. (NASDAQ:ICCM) Stock Now Rated “Hold” by Sell-Side Analysts

Shares of IceCure Medical Ltd. (NASDAQ: ICCM - Get Free Report) have been given an average recommendation of "Hold" by the five research firms that are covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating and three have issued a buy rating on the company. The average 12

READ ARTICLE